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Angiogenesis, the growth of new blood vessels, is necessary for cancerous tumors to keep growing and
spreading. Suppression of abnormal angiogenesis may provide therapeutic strategies for the treatment
of angiogenesis-dependent disorders. In the present study, we describe the in vitro and in vivo anti-
angiogenic activities of the ﬂavonoid precursor 4-hydroxychalcone (Q797). This chalcone (22 mg/ml)
suppressed several steps of angiogenesis, including endothelial cell proliferation, migration and tube
formation without showing any signs of cytotoxicity. Moreover, we found a selective effect on activated
endothelial cells, in particular with resting endothelial cells and the human epithelial tumor cell lines
(HeLa, MCF-7, A549). In addition, Q797 was able to modulate both vascular endothelial growth factor
(VEGF)- and basic ﬁbroblast growth factor (FGF)- induced phosphorylation of extracellular signal-
regulated kinase (ERK)-1/-2 and Akt kinase. It did not inﬂuence the nuclear translocation of p65 subunit
of the nuclear factor-kB (NF-kB) when human endothelial cells were stimulated with tumor necrosis
factor (TNF)-a. Taken together this indicates that the Q797-mediated inhibition of in vitro angiogenic
features of endothelial cells is most likely caused by suppression of growth factor pathways. The potent
inhibitory effect of Q797 on bFGF-driven neovascularization was also demonstrated in vivo using the
chick chorioallantoic membrane (CAM) assay. In summary, this chalcone could serve as a new leading
structure in the discovery of new potent synthetic angiogenesis inhibitors.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Angiogenesis is the outgrowth of new blood vessels from
pre-existing vasculature. It is a necessary process in embryogen-
esis and wound healing but also plays a major role in several
pathologic processes such as tumor vascularisation, diabetic
retinopathy, psoriasis and rheumatoid arthritis (Folkman 1995,
2007). Therefore, newly designed anti-angiogenic agents have
potential for the treatment of a broad spectrum of diseases,
including cancer (Ribatti, 2009).
An increasing interest is devoted to naturally occurring cancer
chemo-preventive agents, including ﬂavonoids, which are rich in
fruits, soybeans, vegetables, herbs, roots and leaves (Hollman and
Katan, 1999; Larsen et al., 2010; Yang et al., 2011). These poly-
phenolic compounds display a remarkable spectrum of biologicalll rights reserved.
.
ska),
.unibs.it (M. Belleri),
hu (P. Perjesi),
l (P. Koolwijk),
s@upjs.sk (J. Mojzis).activities including those that might be able to inﬂuence processes
that are dysregulated during cancer development. They selectively
induce apoptosis in various human carcinoma cell lines and they
are thought to be involved in the suppression of angiogenesis
(Lamoral-Theys et al., 2010).
Many fruits and vegetables are also rich dietary sources of
ﬂavonoid precursors, in particular the chalcones. These com-
pounds could make a great contribution to the total daily intake
of natural polyphenolics (Tomas-Barberan and Clifford, 2010),
since they appear to possess potentially beneﬁcial effects against
various diseases (de Campos-Buzzi et al., 2006; Sharma et al.,
2009). Indeed, they are associated with several biologically active
properties, including anti-inﬂammatory (Hsieh et al., 2000; Won
et al., 2005), anti-oxidative (Nerya et al., 2004), anti-fungal
(Sivakumar et al., 2009a), anti-bacterial (Sivakumar et al., 2009b),
chemo-preventive and anti-cancer activities (Ducki, 2007; Chua
et al., 2010; Katsori and Hadjipavlou-Litina, 2009; Liu and Go,
2006; Modzelewska et al., 2006). Although there are an increasing
number of articles relating the anti-cancer activities of chalcones,
limited information is available about a possible anti-angiogenic
activity of this class of compounds (Kang et al., 2010; Kim et al.,
2010; Mojzis et al., 2008).
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enone moiety and its relative ﬂexibility compared to other related
natural products predispose the template to interactions with
diverse receptors and enzymes (Go et al., 2005), as well as their
biological properties prompted us to investigate whether chal-
cones and newly synthesized cyclic chalcone analogues modulate
angiogenesis in both in vitro and in vivo models. We present for
the ﬁrst time the evidence that one of the chalcones; 4-hydro-
xychalcone (Q797) inhibits different steps of the angiogenesis
process in vitro by affecting both vascular endothelial growth
factor (VEGF) and basic ﬁbroblast growth factor (bFGF) intracel-
lular signaling. In line with this in vitro data, Q797 also caused a
signiﬁcant anti-angiogenic activity in vivo. Q797 may represent
the basis for the design of novel anti-angiogenic chalcone
derivatives.2. Materials and methods
2.1. Chemicals
Medium 199 with 20mM HEPES (M199), penicillin, streptomycin
and newborn calf serum (NBCS) were obtained from Lonza (Verviers,
Belgium). Tissue plastics were from Corning Life Science (Lowell, MA
USA) and L-glutamine from Sigma–Aldrich (St. Louis, MO USA).
Human serum (HS) was obtained from PAA (Pasching, Austria). Basic
ﬁbroblast growth factor (bFGF) was purchased from Sigma–Aldrich
(St. Louis, MO USA), vascular endothelial growth factor (VEGF-A) from
Biosource (Camarillo, CA USA) and tumor necrosis growth factor
(TNF)-a was obtained from R&D Systems (Minneapolis, MN USA).
Matrigel basement membrane matrix was obtained from Becton
Dickinson Labware (Bedford, MA USA). The chalcones: 4-hydroxy-
chalcone (Q797), 4-methylchalcone (Q171), 4-methoxychalcone
(Q126), 4-dimethylaminochalcone (Q192) and the cyclic chalcone
analogues: (E)-2-(X-benzylidene)-1-indanones ((E)-2-(4-dimethyla-
minobenzylidene)-1-indanone (Q560), (E)-2-(4-methoxybenzyli-
dene)-1-indanone (Q397), (E)-2-(4-hydroxybenzylidene)-1-indan
one (Q764)), (E)-2-(2,4-dimethoxybenzylidene)-1-tetralone (Q705),
(E)-2-(X-benzylidene)-1-benzosuberones ((E)-2-(4-methoxybenzyli-
dene)-1-benzosuberone (Q510), (E)-2-(4-hydroxybenzylidene)-1-
benzosuberone (Q766)) were synthesized as described below by dr.
Perjesi (University Medical School of Pecs, Hungary).
Other materials used in the methods described below have
been speciﬁed in detail in related references or in the text or were
purchased from standard commercial sources.
2.1.1. Synthesis of non-hydroxyl substituted chalcones
A methanol solution of sodium hydroxide (0.005 M) was
added to methanol solutions of equimolar (0.01 M) amounts of
acetophenone, cyclic ketone or aromatic aldehyde. The mixture
was allowed to incubate at room temperature for two days, and
precipitated at 4 1C. The dried precipitate was subjected to the
column chromatography over Kieselgel 60 (Merck, Ralway, NJ
USA) and the pure chalcone was crystallized from methanol. The
purity of the compounds was checked by TLC using Merck silica
gel 60 F254 alumina sheets. The structure and stereochemistry of
the compounds was characterized by elemental analysis, IR and
NMR methods (Dimmock et al., 1999; Perjesi et al., 1999).
2.1.2. Synthesis of hydroxyl substituted chalcones
A few drops of piperidine were added to an equimolar (0.01 M)
amount of acetophenone, cyclic ketone or aromatic aldehyde and
the mixture was heated at 120 1C for 1 h. The methanol mixture
was then precipitated at 4 1C. The dried precipitate was subjected
to column chromatography over Kieselgel 60 (Merck, Ralway, NJ
USA), and the pure chalcone was crystallized from hexane (Q797)or methanol (Q764 and Q766). The purity of the compounds was
checked by TLC using Merck silicagel 60 F254 alumina sheets. The
structure and stereochemistry of the compounds were character-
ized by elemental analysis, IR and NMR methods. The synthesized
Q797 and 4-hydroxyindanone had melting points in accord with
the literature values (Dimmock et al., 1998).
2.2. Cell culture
Human foreskin microvascular endothelial cells (hMVEC) and
human umbilical vein endothelial cells (HUVEC) were isolated,
cultured, and characterized as previously described (Deﬁlippi
et al., 1991; van Hinsbergh et al., 1987). Cells were cultured on
gelatine-coated dishes in cM199 (¼M199 medium supplemented
with 10% heat-inactivated human serum, 10% heat-inactivated
new born calf serum, 3.75 mg/ml crude endothelial cell growth
factor (ECGF), 5 U/ml heparin, 100 IU/ml penicillin, and 100 mg/ml
streptomycin) at 37 1C under 5% CO2/95% air atmosphere.
Twenty-four hours prior to experiments endothelial cell cul-
tures were refreshed with medium without crude endothelial cell
growth factor and heparin.
The human cervical adenocarcinoma cell line HeLa was cul-
tured in RPMI-1640 medium (PAA Laboratories, Pasching, Austria)
supplemented with 10% fetal bovine serum and antibiotics
(penicillin 100 U/ml and streptomycin 100 mg/ml; Invitrogen,
Carlsbad, CA USA). Human breast adenocarcinoma cell line MCF-
7 and human lung adenocarcinoma epithelial cell line A549 were
cultured in D-MEM medium (Invitrogen, Carlsbad, CA USA)
supplemented with 10% fetal bovine serum and antibiotics
(penicillin 100 U/ml and streptomycin 100 mg/ml).
2.3. Formation of capillary like tubular structure in a 3-dimensional
matrix
Human ﬁbrin matrices were prepared in the wells of 96-wells
plates by addition of a 100 ml solution of a mixture of 0.1 U/ml
thrombin and 2 mg/ml plasma-derived, plasminogen-depleted
ﬁbrinogen (Calbiochem, La Jolla, CA USA) in M199 medium as
described previously (Koolwijk et al., 1996). After preparation of
the matrices, conﬂuent endothelial cell monolayers (0.7105
cells/cm2) were detached, concentrated and seeded in a 1.25:1
split ratio on the ﬁbrin matrices and cultured for 24 h in M199
supplemented with 10% HS, 10% NBCS, and penicillin/streptomy-
cin before stimulating the cells with serum-containing M199 with
or without (control) 10 ng/ml bFGF or 25 ng/ml VEGF, and 10 ng/ml
TNF-a. Every second or third day, the culture medium was collected
and fresh medium was added. Invading cells and the formation of
tubular structures of endothelial cells in the 3-D ﬁbrin matrix were
analyzed by phase contrast microscopy. The total length of tube-like
structures of 4 randomly chosen microscopic ﬁelds in triplicate
wells was measured using a Nikon FXA microscope equipped with a
monochrome CCD camera (MX5) connected to a computer with
Optimas image analysis software and expressed as mm/cm2.
2.4. In vitro Matrigel angiogenesis assay
The effect of Q797 on the ability of HUVEC to reorganize and
differentiate into capillary-like networks was assessed in the in vitro
Matrigel morphogenesis assay as described previously (Grant et al.,
1989). Matrigel (9.8 mg/ml) was thawed at 4 1C, and 50 ml was
quickly added to wells of a 96-well plate and allowed to solidify
for 30 min at 37 1C. HUVEC were seeded at a cell density of 15,000
cells/well. Medium supplemented with VEGF (25 ng/ml) and differ-
ent concentrations of studied compounds (0.22, 2.2, 22 mg/ml)
was added for 8 h. The formation of capillary-like structures was
examined microscopically and photographs were taken using a
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microscope (Leica Microsystems, Wetzlar, Germany).
2.5. Assessment of monolayer integrity and cell viability
Endothelial cells were seeded and grown to conﬂuence in 24-
wells plates and then treated with serial dilutions of Q797 in
cM199 medium. Pictures of the monolayers were taken using a
camera at the time points 24, 72 and 144 h (Leica Microsystems,
Wetzlar, Germany) and the number of cells were counted.
In parallel, cell viability at 24 h was determined by Trypan blue
exclusion test.
2.6. Two dimensional migration (wound healing) assay
The motility of HUVEC was assayed using a wound healing
assay (Martı´nez-Poveda et al., 2005). Brieﬂy, endothelial cells
were cultured on the 24-well plate in the cM199 medium until
conﬂuent. A 2 mm tip of a pipette was used to wound the
monolayer of cells. Afterwards, the medium was replaced with
fresh ECGF and heparin-free medium containing the studied
compounds at different concentrations in the presence of 25 ng/ml
of recombinant VEGF. The wounded area was photographed at the
start (t¼0 h) and at time point t¼15 h. The migration distance (gap
size) was determined using image analysis software. The experi-
ments were performed in duplicate wells and repeated three times
with cells from different donors.
2.7. Methyl-thiazole-tetrazolium (MTT) assay
The assay conditions were essentially the same as described
previously (Kaspers et al., 1994). Brieﬂy, aliquots of 80 ml cell
suspension (4000 cells/well) were added to 96-well microculture
plates. Twenty-four hours after seeding, 20 ml aliquots of drug
solutions (0.22; 2.2; 22 mg/ml) were added to the HUVEC in
triplicate wells for 6 h. Cultures were then washed and allowed
to grow for the next 42 h. Alternatively cultures were incubatedFig. 1. Chemical structures of chalcones and cywith the compound for 48 h throughout the whole experimental
period. The tumor cell lines (HeLa, MCF-7, A549) were cultured in
the presence or absence of different concentrations of Q797 for
72 h. After 72 h of culturing, 10 ml of the MTT solution (Sigma–
Aldrich, St. Louis MO USA) was added to each well and incubated
for another 4 h. Then, the formazan crystals were dissolved with
100 ml of 10% SDS. The optical density (OD) was measured at
540 nm with an EL-312 microplate reader (Biotek Instruments
Inc., Winooski, VT USA), and cell survival was calculated.2.8. Western blot analysis
Cell lysates for phospho-Akt and phospho-ERK detection were
prepared as follows: equal numbers of HUVEC cultured on gelatin-
coated wells, were washed with ice-cold PBS and lysed using a lysis
buffer containing: 0.02 M Tris/HCl (pH¼8), 0.15 M NaCl, 0.09 M KCl,
2 mM EDTA/NaOH, 5% Igepal (Sigma–Aldrich, St. Louis, MO USA),
0.5% Triton-X-100, 1 mM Na3VO4, 0.05 M NaF, protease inhibitor
cocktail (Sigma–Aldrich, St. Louis, MO USA) and phosphatase inhi-
bitor cocktail. The lysates were clariﬁed by centrifugation at
14,000 rpm during 15min. at 4 1C. Protein concentration was mea-
sured using Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA USA).
Equal amount (20 mg) of protein samples were separated on a 12%
SDS-polyacrylamide gel and electrophoretically transferred (100 V,
2 h) onto a nitrocellulose membrane (Pall Gelman Laboratory, Ann
Arbor, MI USA). Afterwards the membranes were blocked for 1 h
using 5% non-fat dry milk. The following primary antibodies were
used: anti-phospho-ERK1/2 (Cell Signaling Technology, Beverly, MA
USA, 1:2000) or anti-phospho-Akt (Cell Signaling Technology, Bev-
erly, MA USA, 1:2000). The membranes were incubated with the
indicated antibodies in 1% non-fat milk at 4 1C for 18 h. After four
times washing with 0.2% PBS-Tween 20, goat-anti-rabbit-HRP
(Santa-Cruz Biotechnology, Santa Cruz, CA USA, sc-2004, 1:2000) or
goat-anti-mouse-HRP (Dako, Carpinteria, CA USA, p0447, 1:2000)
antibodies were added and membranes were incubated for 2 h at
room temperature. Membranes were washed in 0.2% PBS-Tween 20clic chalcone analogues used in this study.
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(Pierce, Rockford, IL USA) according to manufacturer’s instructions
on X-ray ﬁlm (Pierce, Rockford, IL USA). Signal intensity of p-ERK and
p-Akt was determined densitometrically (software Quantity One,
Bio-Rad) and expressed relative to total ERK or Akt.
2.9. NF-kB (p65 subunit) immunoﬂuorescence staining
HUVEC were cultured to conﬂuence on gelatin-coated glass
cover-slips (14 mm diameter). After washing, the cells were pre-
incubated in medium supplemented with 10% HS and 10% NBCS
with or without 22 mg/ml Q797. After 1 h, the cells were washed
once and stimulated with or without TNF-a (10 ng/ml), in the
presence or absence of Q797 for 1 h. After the incubation, the cells
were ﬁxed with 2% paraformaldehyde, permeabilized using 0.05%
Triton X-100 in PBS for 1 min at a room temperature, washed
with PBS, and then incubated with anti-NF-kB antibody (SC 8008-
FITC, Santa Cruz, 1:250) for 1 h. The cells were then washed and
mounted in Slowfade ProLong Gold antifade reagent with DAPIQ797 (µg/ml)
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Fig. 2. Effect of chalcones and cyclic chalcone analogues on capillary-like tube format
stimulated with 25 ng/ml VEGF and 10 ng/ml TNF-a in the absence (A), or in the pre
26 mg/ml Q766 (¼(E)-2-(4-hydroxybenzylidene)-1-benzosuberone (C), or 22 mg/ml
photographed under a phase contrast microscope. Photographs are representative of
Q797 on TNF-a/VEGF-stimulated (VT) (E) or TNF-a/bFGF-stimulated (BT) (F) capillar
quantiﬁed. Similar results were obtained in three independent experiments (nnn¼Po(Invitrogen, Carlsbad, CA USA). The mean immunoﬂuorescence
intensity (MFI) of the nuclei was determined using the image
analysis program SlideBookTM software (version 4.0.8.1; Intelli-
gent Imaging Innovations, Denver, CO, USA). The MFI of 100
nuclei was determined by generating a mask using the DAPI
staining and was expressed as arbitrary (ﬂuorescent) units (AU).2.10. Chicken embryo chorioallantoic membrane (CAM) assay
Alginate beads (5 ml) containing the sample under test were
placed on top of the CAM of fertilized White Leghorn chicken eggs
at day 10 of incubation (Knoll et al., 1999). After 72 h, blood
microvessels entering the implants within the focal plane of the
CAM were counted in ovo at x 5 magniﬁcation using a STEMI SR
stereomicroscope equipped with an objective f equal to 100 mm
with adapter ring 475070 (Zeiss). The experiments were repeated
at least twice with 7–10 eggs per group.Q797 (µg/ml)
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sence of 28 mg/ml Q510 (¼(E)-2-(4-methoxybenzylidene)-1-benzosuberone) (B),
Q797 (¼4-hydroxychalcone) (D). After 6 day of culture, cell cultures were
three independent experiments. (E) and (F) Effect of increasing concentrations of
y-like tube formation. Tube length (% of VT or BT)7SD of triplicate wells was
0.001).
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Results are expressed as mean7S.D. Statistical analyses of the
data were performed by standard procedures, using a one-way
ANOVA followed by Bonferroni Multiple Comparisons Test. Dif-
ferences were considered signiﬁcant when P values were smaller
than 0.05.B
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Fig. 3. Inﬂuence of Q797 on the monolayer of endothelial cells. HUVEC were
cultured in cM199 medium in the presence or absence of various concentrations
(0.22; 2.2 or 22 mg/ml) of Q797 for 144 h. At 24, 72 and after 144 h pictures were
taken and the cells were counted. The pictures of 22 mg/ml Q797 shown are
representative of two independent experiments (A). The total cell number of
triplicate wells was quantiﬁed (B). Similar results were obtained in two indepen-
dent experiments. Values are mean7SD from 3 cultures in 2 independent
experiments.3. Results
3.1. Effect of chalcones and cyclic chalcone analogues on tube
formation in 3-D ﬁbrin matrices
A series of 10 chalcones or cyclic chalcone analogues were
synthesized differing in their backbone structure and/or chemical
substitutions at positions 2 or 4 (see Fig. 1).
The compounds were screened for their potential anti-angiogenic
activity using an in vitro tube/angiogenesis model (Koolwijk et al.,
1996). In this model, hMVEC invade a three-dimensional human
ﬁbrin matrix and form capillary-like tubular structures when stimu-
lated with TNF-a in the presence of either VEGF or bFGF (Fig. 2A).
Addition of the various chalcones and cyclic chalcone analogues to
the cell culture medium resulted in three different biological
responses: the compounds Q126, Q171, Q192, Q510 and Q705
exerted a potent cytotoxic effect on the endothelial cell monolayer
(see effect of Q510, Fig. 2B). Lowering the concentrations of these
compounds reduced not only their cytotoxic activity but also their
inhibitory capacity on endothelial tube formation. Compounds Q764
and Q766 exerted a limited effect on endothelial tube formation in
the absence of cytotoxicity (Fig. 2C, Q766). Finally, the compounds
Q397, Q560, and Q797 induced a signiﬁcant inhibition in the
formation of endothelial tubular structures invading the matrix
without any sign of cytotoxicity towards the endothelial cells in
the monolayer (Fig. 2D, Q797).
Among the tested compounds, the 4-hydroxychalcone Q797
was shown to be the most effective anti-angiogenic compound
and on the basis of that result, the inhibitory activity of Q797 was
further characterized. This chalcone signiﬁcantly suppressed both
VEGF/TNF-a- (Fig. 2E) and bFGF/TNF-a-induced (Fig. 2F) endothe-
lial tube formation when tested at the concentration of 22 mg/ml
(Po0.001), with no signiﬁcant effect at lower concentrations. For
both stimuli, the inhibition occurred in the absence of any cell
death or change in morphology of the endothelial cell monolayer
adherent to the top of the ﬁbrin matrix (see Fig. 2D).
The lack of cytotoxic activity of Q797 was conﬁrmed when the
compound was added to conﬂuent HUVEC (Fig. 3) and hMVEC
monolayers (data not shown) cultured in gelatin-coated wells.
Also in these experiments, no signiﬁcant decrease in cell number
or increase in cell death, as assessed by trypan blue exclusion
staining, was observed when cells were incubated for up to 72 h
with 22 mg/ml Q797 (data not shown).
3.2. Q797 inhibits endothelial cell migration, proliferation and
morphogenesis
To further assess the anti-angiogenic activity of the chal-
cone analogue, Q797 was tested for its capacity to (i) inhibit
cell migration of a mechanically wounded endothelial cell
monolayer and (ii) to affect endothelial cell morphogenesis in
the Matrigel assay. As shown in Fig. 4A and B, Q797
(22 mg/ml) signiﬁcantly inhibited migration of VEGF-stimu-
lated HUVEC (Po0.001). No effect was observed at lower
concentrations.
Q797 was also tested for its capacity to affect endothelial cell
proliferation. After 48 h of treatment, Q797 (22 mg/ml) signiﬁcantlyinhibited the proliferation of HUVEC (Po0.01) (Fig. 4C). The
inhibitory effect exerted by Q797 was reversible as shown by the
ability of HUVEC to recover their proliferative capacity after 6 h of
incubation with the compound followed by an extensive washing
and incubation with fresh medium. This conﬁrms that Q797 has a
cytostatic effect in the absence of cytotoxicity. Interestingly, Q797
did not exert any cytostatic effect on the human tumor cell lines
HeLa, A549, and MCF7 when tested under the same experimental
conditions (Fig. 4D).
In addition, 22 mg/ml Q797 also prevented the ability of HUVEC to
form cord-like structures when seeded on Matrigel (Fig. 4E). This
inhibition was not observed when lower concentrations of Q797
were used.
3.3. Effect of Q797 on endothelial intracellular signaling
Angiogenesis requires the coordinated activation of various
signaling pathways, including the phosphatidylinositol 3-kinase
(PI3K)/Akt and the ERK signaling pathways (Jiang and Liu, 2008;
Kuida and Boucher, 2004). As shown in Fig. 5, Q797 inhibited
both bFGF- and VEGF-induced Akt and ERK phosphorylation in
HUVEC when tested at the concentration of 22 mg/ml (Po0.001).
In contrast, we did not observe any effect of this chalcone on
nuclear translocation of the p65 subunit of NF-kB when HUVEC
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Fig. 4. Effect of Q797 on different in vitro steps of the angiogenic process. (A) Effect of Q797 on endothelial cells migration in vitro. Conﬂuent monolayers of HUVEC were
wounded. Subsequently, the cells were stimulated with 25 ng/ml VEGF in the presence or absence of Q797 at the indicated concentrations for 15 h. (B) Values are
mean7SD from 2 cultures in 4 independent experiments (nnn¼Po0.001 versus VEGF alone). (C) Effect of Q797 on cell proliferation. HUVEC were incubated in the
presence of increasing concentrations of Q797 for 6 h, washed and allowed to grow for the next 42 h (~), or were incubated with the compound for 48 h throughout the
whole experimental period (’). (D) Different tumor cell lines (HeLa&; MCF-7n; A549 J) were cultured in complete medium in the presence or absence of Q797 at the
indicated concentrations for 72 h. Data are mean7SD of three determinations in duplicate and are expressed as a percentage of absorbance of the untreated control
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L. Varinska et al. / European Journal of Pharmacology 691 (2012) 125–133130were stimulated with TNF-a (Fig. 6), thus conﬁrming the speciﬁcity
of the effect of Q797 on angiogenic growth factor-mediated
signaling.
3.4. Q797 inhibits angiogenesis in vivo
Q797 was assessed for its anti-angiogenic activity in vivo on
the chick embryo CAM. To this purpose, 5 ml alginate beads
containing 150 ng of bFGF in the absence or in the presence of
5.6 mg/ml of chalcone Q797 were applied topically on the CAM at
day 10 of development. As is shown in Fig. 7, bFGF-pellets trigger
a potent angiogenic response that was signiﬁcantly inhibited by
Q797 (Po0.05). Interestingly, Q797 does not exert any effect on
the basal vascularisation of the CAM and does not affect the
development and survival of the chick embryos (data not shown).4. Discussion
In the present study, we demonstrated the in vitro and in vivo
anti-angiogenic activity of the ﬂavonoid precursor 4-hydroxy-
chalcone (Q797). Q797 was one of the 10 compounds that were
tested using the in vitro angiogenesis model in which human
microvascular endothelial cells cultured on ﬁbrin matrices form
capillary-like tubular structures when stimulated with the com-
bination of either VEGF or bFGF and TNF-a (Koolwijk et al., 1996).
Q797 showed potential anti-angiogenic properties on the forma-
tion of tube-like structures of endothelial cells in 3D ﬁbrin
matrices, on the 2D migration of endothelial cells, and on HUVEC
proliferation. This anti-angiogenic capacity of Q797 seemed to be
selective towards activated endothelial cells and not towards
quiescent HUVEC monolayers or the human tumor cell lines
Fig. 5. Q797 inhibits VEGF- and bFGF-induced ERK1/2 and Akt phosphorylation in HUVEC. HUVEC cultured in M199 supplemented with 10% HS and 10% NBCS were pretreated
with the indicated concentrations of Q797 for 1 h and then stimulated with 25 ng/ml of VEGF or 10 ng/ml of bFGF for 15min before collection. Phosphorylated and total Akt (A) or
ERK1/2 (B) were detected by speciﬁc antibodies. The pictures shown are representative of three independent experiments. Western blots were quantiﬁed by densitometry and
ratio of phosphorylated ERK or phosphorylated Akt to their total counterpart was expressed as mean7SD of three experiments. (nnn¼Po0.001).
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Fig. 6. Lack of effect of Q797 on TNFa-induced NF-kB translocation in HUVEC. HUVEC were pretreated with or without 22 mg/ml of Q797 for 1 h in M199 supplemented
with 10% HS and 10% NBCS. Then, cells were washed and incubated with either control medium (control and controlþQ797) or 10 ng/ml TNF-a (TNF-a and TNF-aþQ797)
with or without Q797. After 1 h of incubation, HUVEC were ﬁxed and immunostained with an anti-NF-kB antibody (panel A) and the mean ﬂuorescence intensity (MFI) of
100 nuclei was determined (panel B) using the image analysis program SlideBookTM and was expressed as mean arbitrary (ﬂuorescent) units (AU)7SD. n¼Po0.05 to
control, #¼Po0.05 to controlþQ797.
L. Varinska et al. / European Journal of Pharmacology 691 (2012) 125–133 131HeLa, A549 and MCF-7. Nam et al. (2003) also reported that
20,50-dihydroxychalcone showed some speciﬁcity against HUVEC
since the effective anti-angiogenic concentration of their compoundwas lower than the IC50 value obtained for tumor cell lines.
However, endothelial cell speciﬁcity is not a typical feature of
chalcones, since most of the chalcones studied to date for their
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Fig. 7. Q797 impairs bFGF-induced angiogenesis. CAMs were implanted at day 10
of development with alginate beads containing vehicle (PBS), 150 ng of bFGF,
5.6 mg/ml of Q797 or 150 ng of bFGF added with 5.6 mg/ml of Q797. After 3 day,
CAMs were photographed and angiogenesis was quantiﬁed by counting the
number of microvessels (mean7SD) invading the alginate area. Note the
signiﬁcant reduction by Q797 (n¼Po0.05) in the number of newly-formed
microvessels converging towards the bFGF implant in the presence of the Q797.
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ities (Albini et al., 2006; Bertl et al., 2004; Dell’Eva et al., 2007;
Kim et al., 2010; Kimura and Baba, 2003; Kong et al., 2010; Lee
et al., 2006; Rodrigues et al., 2011; Zhu et al., 2005). These data
suggests that while other chalcones caused a non-selective effect,
4-hydroxychalcone induced a speciﬁc effect on activated
endothelial cells with no cytotoxicity on quiescent cells and
tumor cells.
In our study, the concentration of Q797 needed to inhibit
the formation of tubular structures was high; 22 mg/ml. However,
the anti-angiogenic effect was not caused due to cytotoxicity of
this chalcone. Prolonged incubation of endothelial monolayers
with this concentration of Q797 did not change the morphology
of the cells nor did it induce any cell death.
Zhu et al. (2005) have shown that 20,40-dihydroxy-60-methoxy-
30,50-dimethylchalcone selectively inhibited VEGF-induced
endothelial cell activation via the inhibition of the phosphoryla-
tion of the vascular endothelial growth factor (VEGF) receptor 2,
without having an effect on phosphorylation of the epidermal
growth factor receptor. In the case of the 4-hydroxychalcone
Q797 we did not ﬁnd a selective inhibition of only the VEGF-
induced signal pathway. We show that both bFGF as well as
VEGF-stimulated in vitro tube formation and endothelial cell
proliferation was inhibited. This could be explained by an inter-
ference with both VEGF as well as bFGF signal transduction
cascades. This presumption was conﬁrmed since Q797 treatment
caused the repression of ERK and Akt phosphorylation in the
endothelial cells not only in response to VEGF but also in response
to bFGF, indicating that components of both growth factor path-
ways could be major targets in the molecular mechanism of Q797.
Previous studies have also shown that several chalcones could
inhibit the NF-kB pathway (Albini et al., 2006; Madan et al., 2000;
Noonan et al., 2007). NF-kB is considered to be a common target
of anti-angiogenic drugs (Albini et al., 2007), and since TNF-a is
used in our in vitro angiogenesis model (Koolwijk et al., 1996) we
investigated whether Q797 affected the activation of the tran-
scription factor NF-kB elicited by TNF-a. In contrast to the
ﬁndings of Albini et al. (2006), Madan et al. (2000) and Noonan
et al. (2007), our results show that the Q797 did not suppress
TNF-a-induced nuclear translocation of the p65 subunit of NF-kB.
These data indicate that the inhibitory effect of Q797 is not a
result of inhibition of NF-kB pathway and that speciﬁcity of this
chalcone is on growth factor-triggering angiogenesis.To evaluate the ability of the Q797 to interfere with the
angiogenic process in vivo, we used the CAM assay as a model
of neo-vessel formation, and observed that Q797 signiﬁcantly
reduced the number of newly formed vessels in the CAM. The
effect was observed in the absence of any effect on embryonic
development and survival and Q797 had no harmful effect on
preexisting vessels. This is in accordance with our in vitro ﬁnd-
ings. It is important to note that the use of 5.6 mg/ml of Q797 gave
a signiﬁcant inhibition effect, compared to 22 mg/ml in vitro.
Taken together, our study provides for the ﬁrst time evidence that
in vitro and in vivo administration of the ﬂavonoid precursor
4-hydroxyhalcone caused suppression of growth factor-induced
angiogenesis at a concentration that is not cytotoxic for quiescence
endothelial cells. Moreover, the present study reveals that Q797-
mediated inhibition of in vitro angiogenesis is most likely triggered
by suppression of growth factor pathways: shutting off downstream
signaling cascades crucial for endothelial cell tube formation. Con-
versely, tumor cell proliferation was not signiﬁcantly inﬂuenced even
at the concentration of 22 mg/ml which points to an enhanced
speciﬁcity of this chalcone for endothelial cells.
Further studies will reveal the more detailed mechanism of
action of this compound in particular the non-concentration-
depend inhibition which we observed. There is ongoing research
in our laboratory aimed at to modifying the chemical structure of
Q797 in order to gain a better understanding of the relation
between the chemical structure and the anti-angiogenic proper-
ties of this chalcone. Such studies could lead to development of
new molecules which inhibit endothelial function in pathophy-
siological conditions. Our results indicate that Q797 may be a
promising candidate inhibitor of angiogenesis.Acknowledgments
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